Table 4b.

Comparison of the performances of the low risk (score2<11), high risk (score2≥17)and very high risk (score2≥24) thresholds of the score 2 to select endometriosis patients in the three populations (derivation, internal and external validation).

SCORE 2	Se [95%CI]	Spe [95%CI]	Observed% [95%CI] of population of endometriosis patients	Observed% [95%CI] of population of controls	Observed% [95%CI] in the sample selected by the value of score 2
DERIVATION SAMPLE N = 1682 (880 endometriosis, 802 controls)
<7	92	33	7%[5–9]	33%	14% endometriosis
N = 355	[90–94]	[30–36]	(3% [1–5]DIE)	[30–36]	86% controls
≥17	78	62	79% [76–82]	38%	65% endometriosis
N = 721	[75–81]	[58–65]	(88%[85–91]DIE)	[35–41]	35% controls
≥24	50	82	50% [47–53]	18%	78% endometriosis
N = 558	[47–54]	[80–85]	(54% [49–59] DIE)	[16–20]	22% controls
INTERNAL VALIDATION SAMPLE N = 842 (395 endometriosis, 447 controls)
<7	92	31	8% [5–11]	31%	19% ose
N = 169	[89–94]	[26–35]	(4% [1–7] DIE)	[27–35]	81% controls
≥17	79	57	79% [75–83]	43%	62% endometriosis
N = 507	[75–83]	[52–61]	(88% [83–93]DIE)	[38–48]	38% controls
≥24	52	81	52% [47–57]	18%	71% endometriosis
N = 287	[47–57]	[78–85]	(59%[52–66] DIE)	[14–22]	29% controls
EXTERNAL VALIDATION SAMPLE N = 308 (220 endometriosis, 88 controls)
<7	81*	49	19% [14–23]	49%	NA⁎⁎
N = 86	[75–86]	[38–60]	(14% [4–24] DIE)	[39–59]
≥17	45*	83	45% [38–52]	17%	NA⁎⁎
N = 115	[39–52]	[73–90]	(64% [50–78] DIE)	[9–25]
≥24	35*	93	35% [29–41]	7%	NA⁎⁎
N = 84	[29–42]	[86–98]	(48%[43–53]DIE)	[2–12]

CI: confidence interval, Se : sensitivity, Spe : specificity.

^⁎statistically different from the value in the derivation sample (p<0.05).

^⁎⁎case control study, NA^**: non adapted for a case control study.